Novo Holdings

Novo Holdings

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Working out of Copenhagen, with affiliates in San Francisco and Boston, Novo Holdings is a world-wide life science investor/ venture capital firm.

Novo Holding's mission is to be a supportive owner of the Novo Group companies and to make a growing impact on health, science, and society by generating long-term returns on the assets of the Novo Nordisk Foundation.

Novo Holdings employs investment and business professionals focused on delivering attractive returns for the benefit of the Novo Nordisk Foundation.

Timeline

Funded Companies

Company
Description
Industry
Website
Location
Inogen

Inogen is a Goleta, California-based company founded in 2001. They develop and manufacture lightweight, portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions.

A New Zealand industrial biotechnology company developing a gas fermentation platform for converting concentrated industrial emissions into valuable chemicals.

The Protein Brewery is a Breda-based developer and manufacturer animal-free-based protein based on fungi fermentation processes.

A company creating sustainable design solutions with biomaterials. It was founded in 2013 and is located in San Francisco, California.

A company developing diagnostic monitoring solutions for early diagnosis and treatment of cardiac arrhythmia

Verona Pharma is a London-based biotechnology company working to discover new drugs for the treatment of chronic respiratory diseases.

Verve Therapeutics is a biotechnology company.

7 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Novo Holdings
January 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novo Ventures, the ventures arm of Novo Holdings, today announces its participation in the BioGeneration Ventures (BGV) oversubscribed fourth...
Novo Holdings
December 15, 2020
www.prnewswire.com:443
/PRNewswire/ -- Today, the Novo Holdings REPAIR Impact Fund announces a further investment in MinervaX, a privately held Danish biotechnology company...
Novo Holdings
December 14, 2020
www.prnewswire.com:443
/PRNewswire/ -- Novo Seeds, the early stage investment and company creation team of Novo Holdings, announced today that it has invested in a new portfolio...
Maija Palmer
December 8, 2020
Sifted
It is bigger than the Gates Foundation by assets, and will feature in virtually every biotech company's cap table at some stage.
BioSpace
December 4, 2020
BioSpace
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Dr. Martin W. Edwards, to its Board of Directors.
August 13, 2020
WebWire
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced $70 million in its Series C financing led by Novo Growth, the growth equity arm of Novo Holdings. Soleus Capital also joins the round, along with earlier investors Mayfield, Cota, and Agilent, bringing the company's total funding to more than $120 million. To support Mission Bio's rapid growth, the funds will scale its single-cell multi-omics technology, the Tapestri® Platform, to e...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.